8.62
price down icon0.92%   -0.07
 
loading

Iteos Therapeutics Inc 주식(ITOS)의 최신 뉴스

pulisher
10:04 AM

(ITOS) Trading Advice - news.stocktradersdaily.com

10:04 AM
pulisher
May 19, 2025

Balyasny Asset Management L.P. Buys Shares of 28,350 iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World

May 19, 2025
pulisher
May 19, 2025

Q2 Earnings Forecast for ITOS Issued By Leerink Partnrs - Defense World

May 19, 2025
pulisher
May 18, 2025

Q4 Earnings Forecast for ITOS Issued By Leerink Partnrs - Defense World

May 18, 2025
pulisher
May 18, 2025

The week in pharma: action, reaction and insight – week to May 16 - The Pharma Letter

May 18, 2025
pulisher
May 18, 2025

Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet - MSN

May 18, 2025
pulisher
May 17, 2025

Research Analysts Issue Forecasts for ITOS Q2 Earnings - Defense World

May 17, 2025
pulisher
May 17, 2025

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives $18.83 Average Target Price from Analysts - Defense World

May 17, 2025
pulisher
May 16, 2025

iTeos Therapeutics (NASDAQ:ITOS) Rating Lowered to “Hold” at Leerink Partnrs - Defense World

May 16, 2025
pulisher
May 16, 2025

Leerink Partners Reiterates “Market Perform” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World

May 16, 2025
pulisher
May 15, 2025

ITOS: ITeos Therapeutics Downgraded to Neutral by HC Wainwright & Co. | ITOS Stock News - GuruFocus

May 15, 2025
pulisher
May 14, 2025

iTeos Therapeutics: End To Belrestotug Program Leads To A Hold Rating (NASDAQ:ITOS) - Seeking Alpha

May 14, 2025
pulisher
May 14, 2025

Piper Sandler cuts iTeos stock price target to $12 from $16 - Investing.com Canada

May 14, 2025
pulisher
May 14, 2025

ITeos Therapeutics (ITOS) Sees Price Target Adjustment by Piper Sandler | ITOS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish - NewsBreak: Local News & Alerts

May 14, 2025
pulisher
May 14, 2025

ITeos Therapeutics (ITOS): Analyst Lowers Price Target, Rating R - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Strategic Shift and Strong Financials Position iTeos Therapeutics for Growth - TipRanks

May 14, 2025
pulisher
May 14, 2025

ITeos Therapeutics (ITOS) Downgraded by Leerink Partners | ITOS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

This Wayfair Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday - Benzinga

May 14, 2025
pulisher
May 14, 2025

Leerink Downgrades iTeos Therapeutics to Market Perform From Outperform - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

HC Wainwright Downgrades iTeos Therapeutics to Neutral From Buy - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics (ITOS) Receives Adjusted Price Target from We - GuruFocus

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics (ITOS) Receives Adjusted Price Target from Wells Fargo | ITOS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics (ITOS) Faces Downgrade Following GSK's Decisi - GuruFocus

May 14, 2025
pulisher
May 14, 2025

GSK (GSK) and iTeos Halt Belrestotug Development After Disappoin - GuruFocus

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics price target lowered to $12 from $16 at Piper Sandler - TipRanks

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics (ITOS) Faces Downgrade Following GSK's Decision | ITOS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

GSK (GSK) and iTeos Halt Belrestotug Development After Disappointing Trial Results | GSK Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics (ITOS) Downgraded by Analyst with New Price T - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Leerink downgrades iTeos Therapeutics after termination of TIGIT program - TipRanks

May 14, 2025
pulisher
May 14, 2025

iTeos and GSK halt lung cancer drug development By Investing.com - Investing.com India

May 14, 2025
pulisher
May 14, 2025

GSK, partner iTeos end development programme for lung cancer drug belrestotug - Medical Dialogues

May 14, 2025
pulisher
May 14, 2025

ITeos Therapeutics (ITOS) Downgraded by JP Morgan | ITOS Stock N - GuruFocus

May 14, 2025
pulisher
May 13, 2025

As iTeos, GSK shelve belrestotug, prospects for TIGIT continue to dim - biocentury.com

May 13, 2025
pulisher
May 13, 2025

iTeos Therapeutics: TIGIT Falls, And A Zombie Rises? (NASDAQ:ITOS) - Seeking Alpha

May 13, 2025
pulisher
May 13, 2025

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop - insights.citeline.com

May 13, 2025
pulisher
May 13, 2025

JPMorgan cuts iTeos Therapeutics stock rating to neutral, target to $8 - Investing.com Australia

May 13, 2025
pulisher
May 13, 2025

GSK and iTeos end belrestotug antibody program By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

JPMorgan cuts iTeos Therapeutics stock rating to neutral, target to $8 By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

iTeos Therapeutics (ITOS) Downgraded by JPMorgan Analyst | ITOS Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

GSK, partner iTeos scrap development of lung cancer therapy - NewsBreak: Local News & Alerts

May 13, 2025
pulisher
May 13, 2025

iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash PileITeos Therapeutics (NASDAQ:ITOS) - Benzinga

May 13, 2025
pulisher
May 13, 2025

iTeos and GSK to drop belrestotug + dostarlimab collaboration - The Pharma Letter

May 13, 2025
pulisher
May 13, 2025

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Stu - GuruFocus

May 13, 2025
pulisher
May 13, 2025

iTeos, GSK to shelve TIGIT drug after study setback - BioPharma Dive

May 13, 2025
pulisher
May 13, 2025

ITeos Terminates TIGIT Program After Phase 2 Lung Study Misses PFS Endpoint, Explores Options - Nasdaq

May 13, 2025
pulisher
May 13, 2025

ITeos, GSK discontinue lung cancer therapy development - KFGO

May 13, 2025
pulisher
May 13, 2025

Wedbush Adjusts Price Target on iTeos Therapeutics to $10 From $25, Maintains Outperform Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

GSK (GSK) and iTeos Halt Development of Lung Cancer Drug Combo - GuruFocus

May 13, 2025
pulisher
May 13, 2025

GSK, iTeos Therapeutics End Belrestotug Development Program - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

iTeos stock rises despite clinical trial setback By Investing.com - Investing.com South Africa

May 13, 2025
pulisher
May 13, 2025

iTeos stock rises despite clinical trial setback - Investing.com Australia

May 13, 2025
pulisher
May 13, 2025

iTeos (ITOS) Takes Strategic Steps After Disappointing Study Res - GuruFocus

May 13, 2025
pulisher
May 13, 2025

GSK Ends Small-Molecule Drug Belrestotug Development Program - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

GSK, iTeos End Development of Experimental Lung Cancer Drug - Bloomberg.com

May 13, 2025
$1.16
price down icon 17.27%
$31.18
price down icon 3.94%
$578.71
price down icon 0.54%
$4.10
price down icon 2.24%
$288.77
price down icon 0.25%
$72.94
price down icon 0.11%
자본화:     |  볼륨(24시간):